September 7, 2005 | Posted by

Merck – Back of the Envelope Analysis

I played around with Merck’s financials this morning. It appears that MRK will be able to keep paying the dividend despite major blockbuster expirations (Zocor and Fosomax) without dipping substantially into its $13 billion war chest. Here is my back of the envelope analysis (excel spreadsheet).

Vitaliy N. Katsenelson, CFA

This article is written for educational purposes only. It is not intended as a recommendation to buy or sell securities. Author and/or his employer may have a position in the securities discussed in this article. Security positions may change at any time.

Bookmark and Share

Short URL: http://ContrarianEdge.com/?p=50

  • http://www.blogger.com/profile/11393547 Craig

    Interesting blog. While I focus mostly on the technology sector, a lot of your posts are very insightful (esp. the earnings game). Best of luck with your blog.

    -Craig
    http://techstockblog.blogspot.com/

  • http://www.blogger.com/profile/11393547 Craig

    do you have a rss feed? I was going to add your blog to my newsreader, but did not notice any type of sydication/rss feeds?

Recently Commented

  • Anonymous: SOUNDS TO ME LIKE IT’S TIME TO CASH IN THE PFIZER STOCK.
  • Anonymous: Facebook and Google are very similar and will likely have a very similar cost structure.  This is why...
  • Leigh Drogen: While I tend to agree with the sentiment that the relative multiples of Facebook and Google are...
  • Bryan Daniels: If they added free same day delivery and people didn’t need to leave there house even amazon...
  • Sample Stuff: Chrystler came a long way since this article. sleep aids

Recently Added